✦ LIBER ✦

P495 Efficacy of switching to infliximab in Crohn's disease patients with loss of response to adalimumab

✍ Scribed by Peeters, H.; Louis, E.; Baert, F.; Dewit, O.; Coche, J.-C.; Ferrante, M.; Lambrecht, G.; Colard, A.; Van Gossum, A.; Bossuyt, P.; Moreels, T.; De Vos, M.

Book ID: 123446501
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 50 KB
Volume: 8
Category: Article
ISSN: 1873-9946
DOI: 10.1016/S1873-9946(14)60615-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P173 - Efficacy of adalimumab in patient

P173 - Efficacy of adalimumab in patients with Crohn's disease and failure to therapy with infliximab

✍ P. Cordero Ruiz; C. Catro Marquez; V. Mendez Rufian; L. Castro-Laria; á. Caunedo 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 46 KB

P439 In patients with Crohn's disease, t

P439 In patients with Crohn's disease, timing of switching from infliximab to adalimumab affects prognosis

✍ Takeuchi, K.; Yamada, A.; Suzuki, Y. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 50 KB

Safety and Efficacy of Adalimumab (D2E7)

Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab

✍ Papadakis, Konstantinos A.; Shaye, Omid A.; Vasiliauskas, Eric A.; Ippoliti, And 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 80 KB

Switch to adalimumab in patients with Cr

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

✍ Van Assche, G.; Vermeire, S.; Ballet, V.; Gabriels, F.; Noman, M.; D'Haens, G.; 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 356 KB

Switch to adalimumab in patients with Cr

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

✍ Van Assche, G.; Vermeire, S.; Ballet, V.; Gabriels, F.; Noman, M.; D'Haens, G.; 📂 Article 📅 2011 🏛 BMJ Publishing Group 🌐 English ⚖ 356 KB

## Background: Elective switching between anti-tumour necrosis factor (tnf) agents not necessarily dictated by efficacy or tolerability occurs in clinical practice. a study was undertaken to evaluate prospectively the impact of elective switching of patients with crohn's disease well controlled wit

Factors associated with the loss of resp

Factors associated with the loss of response to infliximab in patients with Crohn’s disease

✍ Koji Sono; Akihiro Yamada; Yasushi Yoshimatsu; Nobuo Takada; Yasuo Suzuki 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 578 KB